Fact Sheet
Improving the science of abuse assessment before a drug is marketed is a unified goal for the FDA and pharmaceutical industry. It is the hope that…
Page
The expertise of a global CRO + local know-how to deliver the highest caliber of clinical development services around the world.
Capability
PRA’s dedicated early phase professionals leverage proven expertise in renal and hepatic impairment to provide clients with high quality ECG…
Poster
Human Abuse Potential (HAP) studies are required for New Drug Approvals of all drugs that have a potential psychoactive effect. The steps of…
Poster
Abuse potential refers to the likelihood for a drug to be used in nonmedical situations for its positive psychoactive effects. PRA Health Sciences’…
Poster
Extended-release (ER) opioid formulations are often targeted for misuse and abuse because they contain high amounts of opioid. An oral…
Poster
Abuse deterrent formulations of opioid medications (ADOs) may help curtail the widespread abuse, misuse, and diversion of these products.With the…
Poster
Abuse of prescription opioids continues to be a serious public health concern, with as many as 12.5 million individuals aged 12 or older reporting…
Resource
14C-radiolabeled (radiocarbon) drug studies are central to defining the disposition of therapeutics in clinical development. Concerns over radiation,…
Poster
Hydrocodone bitartrate (HB) and acetaminophen (APAP) combination products are known to be abused via oral, intranasal, and intravenous…